AstraZeneca: Calquence Plus Chemoimmunotherapy Approved in the US for Patients With Previously Untreated Mantle Cell Lymphoma
January 18, 2025
January 18, 2025
WILMINGTON, Delaware, Jan. 18 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US
* * *
AstraZeneca's CALQUENCE (acalabrutinib) in combination with bendamustine and . . .
* * *
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US
* * *
AstraZeneca's CALQUENCE (acalabrutinib) in combination with bendamustine and . . .